Background and Purpose: Knowledge of the burden and development of post-stroke cognitive impairments (CIs) in the long-term after the first event is limited. We aimed to assess the prevalence of mild CI (MCI) and dementia 7 years after first-ever stroke or transient ischemic attack (TIA), to subclassify the impairments, and to identify predictors for a favorable cognitive outcome. Materials and Methods: During 2007 and 2008, 208 patients with first-ever stroke or TIA without preexisting CI were included. After 1 and 7 years, survivors were invited to a follow-up. Transitions of cognitive status from 1 to 7 years were recorded based on the 3 categories dementia, MCI, or none. Etiologic subclassification was based on clinical cognitive profile, magnetic resonance imaging (MRI) findings, and biomarkers at both time points. Favorable outcome was defined as normal cognitive function or MCI after 7 years with exclusion of those who had progression from normal to MCI. Results: Eighty patients died during follow-up, 12 patients refused further participation. After 7 years, 109 completed follow-up of whom 40 (37%) were diagnosed with MCI and 24 (22%) with dementia. Of the 64 patients diagnosed with CI, 9 were subclassified with degenerative cognitive disease, 13 with vascular disease, and 42 had mixed cognitive disease. In all, 65 patients (60%) had a favorable outcome. In multivariable logistic regression analysis, lower age and lower medial temporal lobe atrophy (MTLA) grade on MRI at 12 months were independently associated with a favorable outcome, adjusted OR (95% CI), 0.94 (0.86–0.92), and 0.55 (0.35–0.85), respectively. Conclusions: Sixty percent of stroke survivors have a favorable cognitive outcome. Lower age and lower MTLA grade on MRI were associated with favorable outcome.

1.
Levine
DA
,
Galecki
AT
,
Langa
KM
,
Unverzagt
FW
,
Kabeto
MU
,
Giordani
B
, et al.
Trajectory of Cognitive Decline After Incident Stroke
.
JAMA
.
2015
Jul
;
314
(
1
):
41
51
.
[PubMed]
0098-7484
2.
Pendlebury
ST
,
Rothwell
PM
;
Oxford Vascular Study
.
Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study
.
Lancet Neurol
.
2019
Mar
;
18
(
3
):
248
58
.
[PubMed]
1474-4422
3.
Desmond
DW
,
Moroney
JT
,
Sano
M
,
Stern
Y
.
Incidence of dementia after ischemic stroke: results of a longitudinal study
.
Stroke
.
2002
Sep
;
33
(
9
):
2254
60
.
[PubMed]
0039-2499
4.
Allan
LM
,
Rowan
EN
,
Firbank
MJ
,
Thomas
AJ
,
Parry
SW
,
Polvikoski
TM
, et al.
Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors
.
Brain
.
2011
Dec
;
134
(
Pt 12
):
3716
27
.
[PubMed]
0006-8950
5.
Mok
VC
,
Lam
BY
,
Wang
Z
,
Liu
W
,
Au
L
,
Leung
EY
, et al.
Delayed-onset dementia after stroke or transient ischemic attack
.
Alzheimers Dement
.
2016
Nov
;
12
(
11
):
1167
76
.
[PubMed]
1552-5260
6.
Srikanth
VK
,
Quinn
SJ
,
Donnan
GA
,
Saling
MM
,
Thrift
AG
.
Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort
.
Stroke
.
2006
Oct
;
37
(
10
):
2479
83
.
[PubMed]
0039-2499
7.
Altieri
M
,
Di Piero
V
,
Pasquini
M
,
Gasparini
M
,
Vanacore
N
,
Vicenzini
E
, et al.
Delayed poststroke dementia: a 4-year follow-up study
.
Neurology
.
2004
Jun
;
62
(
12
):
2193
7
.
[PubMed]
0028-3878
8.
Wagle
J
,
Farner
L
,
Flekkøy
K
,
Bruun Wyller
T
,
Sandvik
L
,
Fure
B
, et al.
Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months
.
Dement Geriatr Cogn Disord
.
2011
;
31
(
5
):
379
87
.
[PubMed]
1420-8008
9.
Mok
VC
,
Lam
BY
,
Wong
A
,
Ko
H
,
Markus
HS
,
Wong
LK
.
Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms
.
Nat Rev Neurol
.
2017
Mar
;
13
(
3
):
148
59
.
[PubMed]
1759-4758
10.
Dufouil
C
,
Chalmers
J
,
Coskun
O
,
Besançon
V
,
Bousser
MG
,
Guillon
P
, et al.;
PROGRESS MRI Substudy Investigators
.
Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy
.
Circulation
.
2005
Sep
;
112
(
11
):
1644
50
.
[PubMed]
0009-7322
11.
Cavalieri
M
,
Schmidt
R
,
Chen
C
,
Mok
V
,
de Freitas
GR
,
Song
S
, et al.;
VITATOPS Trial Study Group
.
B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy
.
Stroke
.
2012
Dec
;
43
(
12
):
3266
70
.
[PubMed]
0039-2499
12.
Xiong
Y
,
Wong
A
,
Cavalieri
M
,
Schmidt
R
,
Chu
WW
,
Liu
X
, et al.
Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities
.
Neurotherapeutics
.
2014
Jul
;
11
(
3
):
606
11
.
[PubMed]
1933-7213
13.
Richard
E
,
Gouw
AA
,
Scheltens
P
,
van Gool
WA
.
Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer’s disease (EVA) study
.
Stroke
.
2010
Mar
;
41
(
3
):
554
6
.
[PubMed]
0039-2499
14.
Sevigny
J
,
Chiao
P
,
Bussière
T
,
Weinreb
PH
,
Williams
L
,
Maier
M
, et al.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
.
Nature
.
2016
Sep
;
537
(
7618
):
50
6
.
[PubMed]
0028-0836
15.
Teuschl
Y
,
Ihle-Hansen
H
,
Matz
K
,
Dachenhausen
A
,
Ratajczak
P
,
Tuomilehto
J
, et al.;
ASPIS Study Group
.
Multidomain intervention for the prevention of cognitive decline after stroke - a pooled patient-level data analysis
.
Eur J Neurol
.
2018
Sep
;
25
(
9
):
1182
8
.
[PubMed]
1351-5101
16.
Tang
EY
,
Amiesimaka
O
,
Harrison
SL
,
Green
E
,
Price
C
,
Robinson
L
, et al.
Longitudinal Effect of Stroke on Cognition: A Systematic Review
.
J Am Heart Assoc
.
2018
Jan
;
7
(
2
):
e006443
.
[PubMed]
2047-9980
17.
Lim
JS
,
Noh
M
,
Kim
BJ
,
Han
MK
,
Kim
S
,
Jang
MS
, et al.
A Methodological Perspective on the Longitudinal Cognitive Change after Stroke
.
Dement Geriatr Cogn Disord
.
2017
;
44
(
5-6
):
311
9
.
[PubMed]
1420-8008
18.
Ihle-Hansen
H
,
Thommessen
B
,
Wyller
TB
,
Engedal
K
,
Øksengård
AR
,
Stenset
V
, et al.
Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment
.
Dement Geriatr Cogn Disord
.
2011
;
32
(
6
):
401
7
.
[PubMed]
1420-8008
19.
Jorm
AF
,
Scott
R
,
Cullen
JS
,
MacKinnon
AJ
.
Performance of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening test for dementia
.
Psychol Med
.
1991
Aug
;
21
(
3
):
785
90
.
[PubMed]
0033-2917
20.
Goldstein
LB
,
Bertels
C
,
Davis
JN
.
Interrater reliability of the NIH stroke scale
.
Arch Neurol
.
1989
Jun
;
46
(
6
):
660
2
.
[PubMed]
0003-9942
21.
Adams
HP
 Jr
,
Biller
J
.
Classification of subtypes of ischemic stroke: history of the trial of org 10172 in acute stroke treatment classification
.
Stroke
.
2015
May
;
46
(
5
):
e114
7
.
[PubMed]
0039-2499
22.
Sulter
G
,
Steen
C
,
De Keyser
J
;
Jacques De Keyser
.
Use of the Barthel index and modified Rankin scale in acute stroke trials
.
Stroke
.
1999
Aug
;
30
(
8
):
1538
41
.
[PubMed]
0039-2499
23.
Folstein
MF
,
Folstein
SE
,
McHugh
PR
.
“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
.
J Psychiatr Res
.
1975
Nov
;
12
(
3
):
189
98
.
[PubMed]
0022-3956
24.
Eddy
JR
,
Sriram
S
.
Clock-drawing and telling time as diagnostic aids
.
Neurology
.
1977
Jun
;
27
(
6
):
595
.
[PubMed]
0028-3878
25.
Reitan
RM
.
RM R. Validity of the trail making test as an indicator of organic brain damage
.
Percept Mot Skills
.
1958
;
8
(
3
):
271
6
. 0031-5125
26.
Randolph
C
,
Tierney
MC
,
Mohr
E
,
Chase
TN
.
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity
.
J Clin Exp Neuropsychol
.
1998
Jun
;
20
(
3
):
310
9
.
[PubMed]
1380-3395
27.
Nasreddine
ZS
,
Phillips
NA
,
Bédirian
V
,
Charbonneau
S
,
Whitehead
V
,
Collin
I
, et al.
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
.
J Am Geriatr Soc
.
2005
Apr
;
53
(
4
):
695
9
.
[PubMed]
0002-8614
28.
Barry
D
,
Bates
ME
,
Labouvie
E
.
FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study
.
Appl Neuropsychol
.
2008
;
15
(
2
):
97
106
.
[PubMed]
0908-4282
29.
Scheltens
P
,
Weinstein
HC
,
Leys
D
.
Neuro-imaging in the diagnosis of Alzheimer’s disease. I. Computer tomography and magnetic resonance imaging
.
Clin Neurol Neurosurg
.
1992
;
94
(
4
):
277
89
.
[PubMed]
0303-8467
30.
Pantoni
L
,
Basile
AM
,
Pracucci
G
,
Asplund
K
,
Bogousslavsky
J
,
Chabriat
H
, et al.
Impact of age-related cerebral white matter changes on the transition to disability — the LADIS study: rationale, design and methodology
.
Neuroepidemiology
.
2005
;
24
(
1-2
):
51
62
.
[PubMed]
0251-5350
31.
Winblad
B
,
Palmer
K
,
Kivipelto
M
,
Jelic
V
,
Fratiglioni
L
,
Wahlund
LO
, et al.
Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
.
J Intern Med
.
2004
Sep
;
256
(
3
):
240
6
.
[PubMed]
0954-6820
32.
Organization
WH
.
The ICD-10 Classification of Mental and Behavioural Disorders: diagnostic criteria for research
.
Geneva
;
1993
.
33.
Barbay
M
,
Diouf
M
,
Roussel
M
,
Godefroy
O
;
GRECOGVASC study group
.
Systematic Review and Meta-Analysis of Prevalence in Post-Stroke Neurocognitive Disorders in Hospital-Based Studies
.
Dement Geriatr Cogn Disord
.
2018
;
46
(
5-6
):
322
34
.
[PubMed]
1420-8008
34.
McHutchison
CA
,
Cvoro
V
,
Makin
S
,
Chappell
FM
,
Shuler
K
,
Wardlaw
JM
.
Functional, cognitive and physical outcomes 3 years after minor lacunar or cortical ischaemic stroke
.
J Neurol Neurosurg Psychiatry
.
2018
.
[PubMed]
0022-3050
35.
Mioshi
E
,
Dawson
K
,
Mitchell
J
,
Arnold
R
,
Hodges
JR
.
The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening
.
Int J Geriatr Psychiatry
.
2006
Nov
;
21
(
11
):
1078
85
.
[PubMed]
0885-6230
36.
Sachdev
PS
,
Blacker
D
,
Blazer
DG
,
Ganguli
M
,
Jeste
DV
,
Paulsen
JS
, et al.
Classifying neurocognitive disorders: the DSM-5 approach
.
Nat Rev Neurol
.
2014
Nov
;
10
(
11
):
634
42
.
[PubMed]
1759-4758
37.
Sachdev
P
,
Kalaria
R
,
O’Brien
J
,
Skoog
I
,
Alladi
S
,
Black
SE
, et al.;
Internationlal Society for Vascular Behavioral and Cognitive Disorders
.
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement
.
Alzheimer Dis Assoc Disord
.
2014
Jul-Sep
;
28
(
3
):
206
18
.
[PubMed]
0893-0341
38.
Barbay
M
,
Taillia
H
,
Nédélec-Ciceri
C
,
Bompaire
F
,
Bonnin
C
,
Varvat
J
, et al.;
GRECOG-VASC Study Group
.
Prevalence of Poststroke Neurocognitive Disorders Using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit
.
Stroke
.
2018
May
;
49
(
5
):
1141
7
.
[PubMed]
0039-2499
39.
Thingstad
P
,
Askim
T
,
Beyer
MK
,
Bråthen
G
,
Ellekjær
H
,
Ihle-Hansen
H
, et al.
The Norwegian Cognitive impairment after stroke study (Nor-COAST): study protocol of a multicentre, prospective cohort study
.
BMC Neurol
.
2018
Nov
;
18
(
1
):
193
.
[PubMed]
1471-2377
40.
Wilson
RS
,
Yang
J
,
Yu
L
,
Leurgans
SE
,
Capuano
AW
,
Schneider
JA
, et al.
Postmortem neurodegenerative markers and trajectories of decline in cognitive systems
.
Neurology
.
2019
Feb
;
92
(
8
):
e831
40
.
[PubMed]
0028-3878
41.
Boyle
PA
,
Yu
L
,
Leurgans
SE
,
Wilson
RS
,
Brookmeyer
R
,
Schneider
JA
, et al.
Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies
.
Ann Neurol
.
2019
Jan
;
85
(
1
):
114
24
.
[PubMed]
0364-5134
42.
Román
GC
,
Tatemichi
TK
,
Erkinjuntti
T
,
Cummings
JL
,
Masdeu
JC
,
Garcia
JH
, et al.
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
.
Neurology
.
1993
Feb
;
43
(
2
):
250
60
.
[PubMed]
0028-3878
43.
McKhann
G
,
Drachman
D
,
Folstein
M
,
Katzman
R
,
Price
D
,
Stadlan
EM
.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease
.
Neurology
.
1984
Jul
;
34
(
7
):
939
44
.
[PubMed]
0028-3878
44.
Larner
AJ
.
Evaluating cognitive screening instruments with the “likelihood to be diagnosed or misdiagnosed” measure
.
Int J Clin Pract
.
2019
Feb
;
73
(
2
):
e13265
.
[PubMed]
1368-5031
45.
Mijajlović
MD
,
Pavlović
A
,
Brainin
M
,
Heiss
WD
,
Quinn
TJ
,
Ihle-Hansen
HB
, et al.
Post-stroke dementia - a comprehensive review
.
BMC Med
.
2017
Jan
;
15
(
1
):
11
.
[PubMed]
1741-7015
46.
Scheltens
P
,
Leys
D
,
Barkhof
F
,
Huglo
D
,
Weinstein
HC
,
Vermersch
P
, et al.
Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates
.
J Neurol Neurosurg Psychiatry
.
1992
Oct
;
55
(
10
):
967
72
.
[PubMed]
0022-3050
47.
Ballard
CG
,
Morris
CM
,
Rao
H
,
O’Brien
JT
,
Barber
R
,
Stephens
S
, et al.
APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment
.
Neurology
.
2004
Oct
;
63
(
8
):
1399
402
.
[PubMed]
0028-3878
48.
Pandya
SY
,
Lacritz
LH
,
Weiner
MF
,
Deschner
M
,
Woon
FL
.
Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition
.
Dement Geriatr Cogn Disord
.
2017
;
43
(
3-4
):
204
14
.
[PubMed]
1420-8008
49.
Ganguli
M
,
Jia
Y
,
Hughes
TF
,
Snitz
BE
,
Chang
CH
,
Berman
SB
, et al.
Mild Cognitive Impairment that Does Not Progress to Dementia: A Population-Based Study
.
J Am Geriatr Soc
.
2018
.
[PubMed]
0002-8614
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.